JP2012521217A5 - - Google Patents

Download PDF

Info

Publication number
JP2012521217A5
JP2012521217A5 JP2012502150A JP2012502150A JP2012521217A5 JP 2012521217 A5 JP2012521217 A5 JP 2012521217A5 JP 2012502150 A JP2012502150 A JP 2012502150A JP 2012502150 A JP2012502150 A JP 2012502150A JP 2012521217 A5 JP2012521217 A5 JP 2012521217A5
Authority
JP
Japan
Prior art keywords
antibody
composition
antigen
binding fragment
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012502150A
Other languages
English (en)
Japanese (ja)
Other versions
JP5830460B2 (ja
JP2012521217A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/028200 external-priority patent/WO2010111198A1/en
Publication of JP2012521217A publication Critical patent/JP2012521217A/ja
Publication of JP2012521217A5 publication Critical patent/JP2012521217A5/ja
Application granted granted Critical
Publication of JP5830460B2 publication Critical patent/JP5830460B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012502150A 2009-03-23 2010-03-23 癌および線維性疾患を治療する化合物、組成物、および方法 Expired - Fee Related JP5830460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16234809P 2009-03-23 2009-03-23
US61/162,348 2009-03-23
PCT/US2010/028200 WO2010111198A1 (en) 2009-03-23 2010-03-23 Compounds compositions and methods of treating cancer and fibrotic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015159597A Division JP2016034945A (ja) 2009-03-23 2015-08-12 癌および線維性疾患を治療する化合物、組成物、および方法

Publications (3)

Publication Number Publication Date
JP2012521217A JP2012521217A (ja) 2012-09-13
JP2012521217A5 true JP2012521217A5 (enExample) 2013-05-09
JP5830460B2 JP5830460B2 (ja) 2015-12-09

Family

ID=42288813

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012502150A Expired - Fee Related JP5830460B2 (ja) 2009-03-23 2010-03-23 癌および線維性疾患を治療する化合物、組成物、および方法
JP2015159597A Pending JP2016034945A (ja) 2009-03-23 2015-08-12 癌および線維性疾患を治療する化合物、組成物、および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015159597A Pending JP2016034945A (ja) 2009-03-23 2015-08-12 癌および線維性疾患を治療する化合物、組成物、および方法

Country Status (8)

Country Link
US (3) US8444983B2 (enExample)
EP (1) EP2411413B1 (enExample)
JP (2) JP5830460B2 (enExample)
CN (2) CN104861066B (enExample)
CA (1) CA2753388C (enExample)
IL (2) IL215061A0 (enExample)
SG (1) SG174367A1 (enExample)
WO (1) WO2010111198A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5830460B2 (ja) 2009-03-23 2015-12-09 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 癌および線維性疾患を治療する化合物、組成物、および方法
JP2015509085A (ja) * 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
EP3003350B1 (en) * 2013-05-27 2018-02-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Targeted modulation of macrophages
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
CA2942101A1 (en) 2014-03-21 2015-09-24 Abbvie Inc. Anti-egfr antibodies and antibody drug conjugates
US20170266166A1 (en) * 2014-05-17 2017-09-21 University Of Rochester Compositions and Methods to Inhibit Estrogen Receptor Beta for the Treatment of Renal Cell Carcinoma
CA2960466C (en) * 2014-09-08 2023-09-05 National Cancer Center Cancer cell-specific antibody, anticancer drug and cancer testing method
ES2874668T3 (es) 2016-02-05 2021-11-05 Rigshospitalet Conjugados anticuerpo-fármaco dirigidos a uPARAP
EP3468993A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
IL300274A (en) 2016-06-08 2023-04-01 Abbvie Inc Antibodies against B7–H3 and conjugates of drug and antibody
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
EP3468598A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CN118562004A (zh) 2016-12-16 2024-08-30 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
CA3064697A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
JP7232453B2 (ja) * 2017-09-15 2023-03-03 学校法人杏林学園 糖尿病網膜症、白内障及び／又は腎症モデル実験動物
JP7674354B2 (ja) * 2019-12-05 2025-05-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 肝線維症および線維症に関連する他の疾患に対するエキソソームベースの療法
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2023275112A1 (en) 2021-06-29 2023-01-05 Rigshospitalet Antibody-drug conjugates comprising humanized antibodies targeting urokinase type plasminogen activator receptor associated protein (uparap)
CN120456932A (zh) 2022-12-28 2025-08-08 艾德森多有限公司 包含依喜替康衍生物的靶向uPARAP的抗体偶联药物
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof
EP4578463A1 (en) * 2023-12-29 2025-07-02 Oncomatryx Biopharma, S.L. Endo-180 targeted antibody-drug conjugates
WO2025141153A1 (en) * 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL81370A (en) * 1986-02-07 1991-06-30 Genetic Systems Corp Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5773268A (en) * 1994-11-09 1998-06-30 Cedars-Sinai Medical Center Chromosome 21 gene marker, compositions and methods using same
US6117977A (en) 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
ZA973051B (en) 1996-04-24 1998-10-12 Genentech Inc Type c lectins
US20050042647A1 (en) 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US6077508A (en) 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
DE50015293D1 (de) 1999-04-13 2008-09-11 Wilex Ag Diagnostischer und therapeutischer Einsatz von Antikörpern gegen den Urokinase-Rezeptor
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US7544374B2 (en) 2001-08-14 2009-06-09 Tel Aviv University Future Technology Development L.P. Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
US20040248835A1 (en) 2001-10-26 2004-12-09 Anja Krebs Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
US7795422B2 (en) 2002-02-20 2010-09-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US7452987B2 (en) 2002-08-05 2008-11-18 Silence Therapeutics Aktiengesellschaft (Ag) Interfering RNA molecules
US8729036B2 (en) 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
EP2213738B1 (en) 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
EP1624788A2 (en) 2003-05-19 2006-02-15 Quark Biotech, Inc. Use of endo180 receptor for diagnosis and treatment of disease
US7842800B2 (en) 2004-04-02 2010-11-30 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof
US8808664B2 (en) 2004-07-13 2014-08-19 Ramot At Tel-Aviv University Ltd. Lipidated glycoprotein particles and methods of use
EP1789447B1 (en) 2004-08-16 2012-04-25 Immune Disease Institute, Inc. Method of delivering rna interference and uses thereof
WO2006050246A2 (en) 2004-11-02 2006-05-11 Tel-Aviv University Future Technology Development L.P. Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles, their manufacturing and their use for diagnostics and therapy
WO2008020435A2 (en) 2006-08-15 2008-02-21 Quark Pharmaceuticals, Inc Compositions and methods for treatment of mood disorders
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US20100292301A1 (en) 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
WO2008109105A2 (en) * 2007-03-06 2008-09-12 Flagship Ventures Methods and compositions for improved therapeutic effects with sirna
US8614309B2 (en) 2007-10-03 2013-12-24 Quark Pharmaceuticals, Inc. Double-stranded RNA directed to CASP2 and methods of use thereof
US8632803B2 (en) * 2008-02-27 2014-01-21 Ramot At Tel-Aviv University Ltd. System for delivery of protein in insoluble fibrillar or aggregate form
JP5830460B2 (ja) 2009-03-23 2015-12-09 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 癌および線維性疾患を治療する化合物、組成物、および方法
EP2504435B1 (en) 2009-11-26 2019-11-13 Quark Pharmaceuticals, Inc. Sirna compounds comprising terminal substitutions

Similar Documents

Publication Publication Date Title
JP2012521217A5 (enExample)
JP7458399B2 (ja) 抗クローディン抗体及びそれらの使用
TWI853077B (zh) 新型抗ｃｄ３９抗體
JP2012121878A5 (enExample)
JP2017526339A5 (enExample)
JP2012034692A5 (enExample)
JP2017507936A5 (enExample)
RU2012137515A (ru) Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
JP2017519501A5 (enExample)
JP2012100675A5 (enExample)
JP2016512425A5 (enExample)
JP2009225799A5 (enExample)
JP2011502137A5 (enExample)
JP2014039548A5 (enExample)
JP2010511388A5 (enExample)
JP2010533498A5 (enExample)
JP2010523541A5 (enExample)
JP2009521206A5 (enExample)
JP2013121353A5 (enExample)
JP2018502060A5 (enExample)
JP2011509245A5 (enExample)
JP2016116536A5 (enExample)
JP2012100677A5 (enExample)
HRP20170254T1 (hr) Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
JP2010513303A5 (enExample)